A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Clinical trial NCT00726869 · TERMINATED

Trial details

NCT number: NCT00726869
Sponsor: Abbott
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2008-05-01
Primary completion: 2012-03-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.